Rapid virological&End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C

about

Rapid virological&End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C

Item

http://www.wikidata.org/entity/Q42669690

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Rapid virological&End treatmen ...... osbuvir in Chronic Hepatitis C

@en

Rapid virological&End treatmen ...... osbuvir in Chronic Hepatitis C

@nl

type

Item

label

Rapid virological&End treatmen ...... osbuvir in Chronic Hepatitis C

@en

Rapid virological&End treatmen ...... osbuvir in Chronic Hepatitis C

@nl

prefLabel

Rapid virological&End treatmen ...... osbuvir in Chronic Hepatitis C

@en

Rapid virological&End treatmen ...... osbuvir in Chronic Hepatitis C

@nl

P1476

Rapid virological&End treatmen ...... osbuvir in Chronic Hepatitis C

@en

P2093

Alvia Saad

http://www.w3.org/2001/XMLSchema#string

Hamna Javed Iqbal

http://www.w3.org/2001/XMLSchema#string

Muhammad Shoaib Siddique

http://www.w3.org/2001/XMLSchema#string

Noureen Durrani

http://www.w3.org/2001/XMLSchema#string

Sana Shoaib

http://www.w3.org/2001/XMLSchema#string

P2860

Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential

Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis

Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS

Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

Sofosbuvir for previously untreated chronic hepatitis C infection

Hepatitis C virus NS5A inhibitors and drug resistance mutations.

Global distribution and prevalence of hepatitis C virus genotypes.

Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

P304

813-817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12669/PJMS.334.12785

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29067045

http://www.w3.org/2001/XMLSchema#string

P921

sofosbuvir

virology

P932

5648944

http://www.w3.org/2001/XMLSchema#string